Clinical Trial Update: A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ropinirole controlled-release (18-24 mg/day) for Parkinson disease was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Ropinirole CR (ropinirole)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Parkinson Disease | Phase 3 | Status: TERMINATED | Results posted: 2015-05-21